The COVID-19 pandemic will drive reforms and open investment opportunities for ASEAN’s healthcare sector, particularly in the fields of biotechnology, telehealth, pharmaceuticals, and diagnostic medicine.
According to the World Health Organization, ASEAN spends close to four percent of its GDP on healthcare, with Singapore at the top of the list with expenditure per capita at US$2,700.
- COVID-19 will encourage reforms in ASEAN’s healthcare sector, opening new investment opportunities in the fields of biotechnology, telehealth, pharmaceuticals, and diagnostic medicine, among others.
- ASEAN members are slowly committing to universal healthcare systems with Indonesia having the largest free healthcare program in the world, covering some 180 million people.
- The region already spends close to four percent of GDP on healthcare, which is expected to increase as consumers become more health-conscious.
Increasing health coverage
ASEAN countries are slowly committing to universal healthcare systems and these national health insurance systems have become a key driver in changing the behavior of ASEAN populations towards health.
This has resulted in consumers becoming more health-conscious in addition to demanding and spending more on health services.
Major markets, such as Indonesia and the Philippines, have succeeded in implementing their national insurance programs; Indonesia’s programs are considered the largest in the world, covering more than 180 million people.
Virtually the whole of Thailand’s population is covered for primary and hospital care and Singapore offers the most advanced levels of healthcare for its citizens, providing specialized treatment, such as heart transplants and neurological procedures.
Singapore, Malaysia, and Thailand lead the field in the medical tourism sector with the three countries having around 100 Joint Commission International (JCI) accredited healthcare centers combined. Being JCI certified is considered the gold standard for patient healthcare and safety.
Foreign patients arrive in the region annually, providing a major source of income for private hospitals, accounting for some 40 percent of revenue in the aforementioned countries.
Globally, the medical tourism industry was worth some US$28 billion, with nearly one-third of the 11 million global medical consumers travelling to Southeast Asia.
The bloc’s pharmaceutical industry is valued at just over US$25 billion, accounting for some 2.2 percent of the global market.
Generic drugs account for a large percentage of the industry’s revenue in the region. However, only a small number of manufacturers have the capabilities to manufacture active pharmaceutical ingredients, with the majority importing ingredients from China or India.
This will open the region for domestic players to increase collaboration with multinational life science companies to serve their local markets. Business models will become more flexible as the use of multi-channel marketing sales, such as e-commerce becomes the new norm.
According to BMI Research, ASEAN’s medical devices industry is expected to see generate more than US$8 billion in revenue in 2021.
In 2015, the bloc established the ASEAN Medical Device Directive (AMDD), a set of directives that aim to harmonize regulations across the region and require medical device manufacturers to register their devices in any member state where they have production. So far, only Singapore, Malaysia, and Indonesia have complied with the AMDD.
The opportunities in the medical devices industry vary depending on the development of each economy. Considering this, product segmentation is an important strategy to enter individual markets.
Chronic diseases, such as diabetes and cardiovascular disease caused by sedentary lifestyles, are becoming more prominent in ASEAN. New solutions include the use of robotic surgery, 3D printing, and implantable devices in addition to other innovations for prevention, which will rapidly transform the industry.
Producers of high-end products can focus on wealthy Singapore as well as the middle-income economies of Thailand and Malaysia, whereas lower-end devices would fare more in the price-sensitive markets of Indonesia, Vietnam, and the Philippines.
This article was first published by ASEAN Briefing, which is produced by Dezan Shira & Associates. The firm assists foreign investors throughout Asia from offices across the world, including in in China, Hong Kong, Vietnam, Singapore, India, and Russia. Readers may write [email protected] for more support.
Skin-lightening products market to reach US$31 billion by 2024
In emerging Asian and African economies, the natural aspiration to enhance one’s circumstances has led to rapid growth in the market for skin-lightening products, which is projected to reach US$31 billion by 2024.
Has Covid-19 prompted the Belt and Road Initiative to go green?
– Chinese overseas investment dropped off in 2020
– Government remains committed to the wide-ranging infrastructure programme
– Sustainability, health and digital to be the new cornerstones of the initiative
Following a year of coronavirus-related disruptions, China appears to be placing a greater focus on sustainable, digital and health-related projects in its flagship Belt and Road Initiative (BRI).
As OBG outlined in April last year, the onset of Covid-19 prompted questions about the future direction of the BRI.
Launched in 2013, the BRI is an ambitious international initiative that aims to revive ancient Silk Road trade routes through large-scale infrastructure development.
By the start of 2020 some 2951 BRI-linked projects – valued at a total of $3.9trn – were planned or under way across the world.
However, as borders closed and lockdowns were imposed, progress stalled on a number of major BRI infrastructure developments.
In June China’s Ministry of Foreign Affairs announced that 30-40% of BRI projects had been affected by the virus, while a further 20% had been “seriously affected”. Restrictions on the flow of Chinese workers and construction supplies were cited as factors behind project suspensions or slowdowns in Pakistan, Cambodia and Indonesia, among other countries.
Marijuana could generate up to Bt8 billion for Thailand’s pharmaceutical industry
Last year, Thailand removed cannabis and hemp leaves from its list of banned narcotics (seeds and buds remain banned).
ASEAN, China reaffirm commitment to strong partnership
The implementation of the new Plan of Action for the period 2021-2025, which is designed to further strengthen ASEAN-China cooperation...
Thailand sees gradual return of events and festivals
The Tourism Authority of Thailand (TAT) would like to provide an update regarding the gradual return of events and festivals...
Thailand’s Stock Exchange (SET)’s board elects Prasarn Trairatvorakul as new Chairman
The Stock Exchange of Thailand (SET)'s Board of Governors (BoG) today resolved to elect Prasarn Trairatvorakul as the 17th Chairman...
Foreigners’ Participation in Thai Listed Companies explained
Special vehicles have been created to facilitate foreign investors so that they are able to invest in Thai securities flexibly...
Gambling in Asia: Thailand and more
There is a large demand for gambling throughout Asia, which is detailed below in a comparison between various countries, such...
EEC Expects 300-billion-baht Investment This Year
BANGKOK (NNT) – Thailand expects investment to triple to at least 300 billion baht in the Eastern Economic Corridor (EEC)...
Subscribe via Email
Economics7 days ago
1.7 million Thais without smartphones register for "Rao Chana" benefits
United States6 days ago
US pledges to enhance cooperation with Mekong subregion’s countries
Startups6 days ago
Traveloka to launch financial services in Vietnam and Thailand
China1 week ago
Mainland China is in no position to take Taiwan by force